{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:30:58Z","timestamp":1783603858426,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T00:00:00Z","timestamp":1561248000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T00:00:00Z","timestamp":1561248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1P01HL116263"],"award-info":[{"award-number":["1P01HL116263"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR000445"],"award-info":[{"award-number":["UL1 TR000445"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR002243"],"award-info":[{"award-number":["UL1 TR002243"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00467-019-04289-5","type":"journal-article","created":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T23:02:56Z","timestamp":1561244576000},"page":"2351-2360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Urinary apolipoprotein AI in children with kidney disease"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6550-730X","authenticated-orcid":false,"given":"Amanda J.","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Jabs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy E.","family":"Hunley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah P.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene G.","family":"VanDeVoorde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes B.","family":"Fogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Kon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,23]]},"reference":[{"key":"4289_CR1","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1161\/CIRCULATIONAHA.116.025678","volume":"135","author":"AV Khera","year":"2007","unstructured":"Khera AV, Demler OV, Adelman SJ, Collins HL, Glynn RJ, Ridker PM, Rader DJ, Mora S (2007) Cholesterol efflux capacity, high-density lipoprotein particle number, and incident cardiovascular events: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating Rosuvastatin). Circulation 135:2494\u20132504","journal-title":"Circulation"},{"key":"4289_CR2","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","volume":"371","author":"A Rohatgi","year":"2014","unstructured":"Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW (2014) HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 371:2383\u20132393","journal-title":"N Engl J Med"},{"key":"4289_CR3","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.3892\/mmr.2015.3930","volume":"12","author":"L Zhou","year":"2015","unstructured":"Zhou L, Li C, Gao L, Wang A (2015) High-density lipoprotein synthesis and metabolism (review). Mol Med Rep 12:4015\u20134021","journal-title":"Mol Med Rep"},{"key":"4289_CR4","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"E Di Angelantonio","year":"2009","unstructured":"Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302:1993\u20132000","journal-title":"JAMA"},{"key":"4289_CR5","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670\u20131681","journal-title":"Lancet"},{"key":"4289_CR6","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1253\/circj.CJ-13-1025","volume":"77","author":"W Annema","year":"2013","unstructured":"Annema W, von Eckardstein A (2013) High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. Jpn Circ J 77:2432\u20132448","journal-title":"Jpn Circ J"},{"key":"4289_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nri3793","volume":"15","author":"AR Tall","year":"2015","unstructured":"Tall AR, Yvan-Charvet L (2015) Cholesterol, inflammation and innate immunity. Nat Rev Immunol 15:104\u2013116","journal-title":"Nat Rev Immunol"},{"key":"4289_CR8","doi-asserted-by":"publisher","first-page":"21237","DOI":"10.1074\/jbc.M113.468967","volume":"288","author":"M Zamanian-Daryoush","year":"2013","unstructured":"Zamanian-Daryoush M, Lindner D, Tallant TC, Wang Z, Buffa J, Klipfell E, Parker Y, Hatala D, Parsons-Wingerter P, Rayman P, Yusufishaq MS, Fisher EA, Smith JD, Finke J, DiDonato JA, Hazen SL (2013) The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol Chem 288:21237\u201321252","journal-title":"J Biol Chem"},{"key":"4289_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/MOL.0000000000000253","volume":"27","author":"KA Rye","year":"2016","unstructured":"Rye KA, Barter PJ, Cochran BJ (2016) Apolipoprotein A-I interactions with insulin secretion and production. Curr Opin Lipidol 27:8\u201313","journal-title":"Curr Opin Lipidol"},{"key":"4289_CR10","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1161\/01.ATV.0000091338.93223.E8","volume":"23","author":"A Kontush","year":"2003","unstructured":"Kontush A, Chantepie S, Chapman MJ (2003) Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 23:1881\u20131888","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4289_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1161\/CIRCRESAHA.116.308357","volume":"119","author":"JS Monette","year":"2016","unstructured":"Monette JS, Hutchins PM, Ronsein GE, Wimberger J, Irwin AD, Tang C, Sara JD, Shao B, Vaisar T, Lerman A, Heinecke JW (2016) Patients with coronary endothelial dysfunction have impaired cholesterol efflux capacity and reduced HDL particle concentration. Circ Res 119:83\u201390","journal-title":"Circ Res"},{"key":"4289_CR12","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1582-4934.2009.00713.x","volume":"14","author":"JA de Souza","year":"2010","unstructured":"de Souza JA, Vindis C, Negre-Salvayre A, Rye KA, Couturier M, Therond P, Chantepie S, Salvayre R, Chapman MJ, Kontush A (2010) Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. J Cell Mol Med 14:608\u2013620","journal-title":"J Cell Mol Med"},{"key":"4289_CR13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S2213-8587(15)00126-6","volume":"3","author":"D Saleheen","year":"2015","unstructured":"Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A, Lukmanova D, Mucksavage ML, Luben R, Billheimer J, Kastelein JJ, Boekholdt SM, Khaw KT, Wareham N, Rader DJ (2015) Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol 3:507\u2013513","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4289_CR14","doi-asserted-by":"publisher","unstructured":"Tsuchida Y, Zhong J, Otsuka T, Dikalova A, Pastan I, Anantharamaiah GM, Linton MF, Yancey PG, Ikizler TA, Fogo AB, Yang H, Kon V (2019) Lipoprotein modulation of proteinuric renal injury. Lab Investig. https:\/\/doi.org\/10.1038\/s41374-019-0253-6","DOI":"10.1038\/s41374-019-0253-6"},{"key":"4289_CR15","doi-asserted-by":"publisher","first-page":"R514","DOI":"10.1152\/ajpregu.00445.2013","volume":"307","author":"RS Moreira","year":"2014","unstructured":"Moreira RS, Irigoyen M, Sanches TR, Volpini RA, Camara NO, Malheiros DM, Shimizu MH, Seguro AC, Andrade L (2014) Apolipoprotein A-I mimetic peptide 4F attenuates kidney injury, heart injury, and endothelial dysfunction in sepsis. Am J Physiol Regul Integr Comp Physiol 307:R514\u2013R524","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"4289_CR16","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.kint.2015.12.043","volume":"89","author":"AC Souza","year":"2016","unstructured":"Souza AC, Bocharov AV, Baranova IN, VIshnyakova TG, Huang YG, Wilkins KJ, Hu X, Street JM, Alvarex-Prats A, Mullick AE, Patterson AP, Remaley AT, Eggerman TL, Yuen PS, Star RA (2016) Antagonism of scavenger receptor CD36 by 5A peptide prevents chronic kidney disease progression in mice independent of blood pressure regulation. Kidney Int 89:809\u2013822","journal-title":"Kidney Int"},{"key":"4289_CR17","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.2337\/db13-0399","volume":"62","author":"S Merscher-Gomez","year":"2013","unstructured":"Merscher-Gomez S, Guzman J, Pedigo CE, Lehto M, Aquillon-Prada R, Mendez A, Lassenius MI, Forsblom C, Yoo T, Villarreal R, Maiguel D, Johnson K, Goldberg R, Nair V, Randolph A, Kretzler M, Nelson RG, Burke GW 3rd, Groop PH, Fornoni A, FinnDiane Study Group (2013) Cyclodextrin protects podocytes in diabetic kidney disease. Diabetes 62:3817\u20133827","journal-title":"Diabetes"},{"key":"4289_CR18","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1172\/JCI85939","volume":"126","author":"CE Pedigo","year":"2016","unstructured":"Pedigo CE, Ducasa GM, Leclercq F, Sloan A, Mitrofanova A, Hashmi T, Molina-David J, Ge M, Lassenius MI, Forsblum C, Lehto M, Groop PH, Kretzler M, Eddy S, Martini S, Reich H, Wahl P, Ghiggeri G, Faul C, Burke GW 3rd, Kretz O, Huber TB, Mendez AJ, Merscher S, Fornoni A (2016) Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury. J Clin Invest 126:3336\u20133350","journal-title":"J Clin Invest"},{"key":"4289_CR19","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.kint.2018.06.031","volume":"94","author":"A Mitrofanova","year":"2018","unstructured":"Mitrofanova A, Molina J, Varona Santos J, Guzman J, Morales XA, Ducasa GM, Bryn J, Sloan A, Volosenco I, Kim JJ, Ge M, Mallela SK, Kretzler M, Eddy S, Martini S, Wahl P, Pastori S, Mendez AJ, Burke GW, Merscher S, Fornoni A (2018) Hydroxypropyl-beta-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis. Kidney Int 94:1151\u20131159","journal-title":"Kidney Int"},{"key":"4289_CR20","doi-asserted-by":"publisher","first-page":"12003","DOI":"10.1074\/jbc.275.16.12003","volume":"275","author":"SM Hammad","year":"2000","unstructured":"Hammad SM, Barth JL, Knaak C, Argraves WS (2000) Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins. J Biol Chem 275:12003\u201312008","journal-title":"J Biol Chem"},{"key":"4289_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.kint.2015.11.007","volume":"89","author":"R Nielsen","year":"2016","unstructured":"Nielsen R, Christensen EI, Birn H (2016) Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease. Kidney Int 89:58\u201367","journal-title":"Kidney Int"},{"key":"4289_CR22","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1681\/ASN.2013060671","volume":"25","author":"O Aseem","year":"2014","unstructured":"Aseem O, Smith BT, Cooley MA, Wilkerson BA, Argraves KM, Remaley AT, Argraves WS (2014) Cubilin maintains blood levels of HDL and albumin. J Am Soc Nephrol 25:1028\u20131036","journal-title":"J Am Soc Nephrol"},{"key":"4289_CR23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11745-008-3169-2","volume":"43","author":"GJ Heilskov","year":"2008","unstructured":"Heilskov GJ, Graciela C, Abdelmejid K, Henning N, Ils\u00f8 CE, Anthony N, Kragh MS (2008) A pivotal role of the human kidney in catabolism of HDL protein components apolipoprotein A-I and A-IV but not of A-II. Lipids 43:467\u2013470","journal-title":"Lipids"},{"key":"4289_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/MNH.0000000000000217","volume":"25","author":"H Yang","year":"2016","unstructured":"Yang H, Fogo AB, Kon V (2016) Kidneys: key modulators of high-density lipoprotein levels and function. Curr Opin Nephrol Hypertens 25:174\u2013179","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"4289_CR25","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/clinchem\/34.9.1775","volume":"34","author":"ZA Gomo","year":"1988","unstructured":"Gomo ZA, Henderson LO (1988) High-density lipoprotein apolipoproteins in urine: II. Enzyme-linked immunoassay of apolipoprotein A-I. Clin Chem 34:1781\u20131786","journal-title":"Clin Chem"},{"key":"4289_CR26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1681\/ASN.V132461","volume":"13","author":"F Kronenberg","year":"2002","unstructured":"Kronenberg F, Kuen E, Ritz E, Konig P, Kraatz G, Lhotta K, Mann JF, Muller GA, Neyer U, Riegel W, Riegler P, Schwenger V, von Eckardstein A (2002) Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. J Am Soc Nephrol 13:461\u2013469","journal-title":"J Am Soc Nephrol"},{"key":"4289_CR27","doi-asserted-by":"publisher","first-page":"8734","DOI":"10.1038\/s41598-017-07213-9","volume":"7","author":"S Mack","year":"2017","unstructured":"Mack S, Coassin S, Vaucher J, Kronenberg F, Lamina C (2017) Evaluating the causal relation of ApoA-IV with disease-related traits - a bidirectional two-sample Mendelian randomization study. Sci Rep 7:8734","journal-title":"Sci Rep"},{"key":"4289_CR28","volume":"2014","author":"W Zhu","year":"2014","unstructured":"Zhu W, Liu M, Wang GC, Peng B, Yan Y, Che JP, Ma QW, Yao XD, Zheng JH (2014) Fibrinogen alpha chain precursor and apolipoprotein A-I in urine as biomarkers for noninvasive diagnosis of calcium oxalate nephrolithiasis: a proteomics study. Biomed Res Int 2014:415651","journal-title":"Biomed Res Int"},{"key":"4289_CR29","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/joim.12290","volume":"277","author":"L Calabresi","year":"2015","unstructured":"Calabresi L, Simonelli S, Conca P, Busnach G, Cabibbe M, Gesualdo L, Gigante M, Penco S, Veglia F, Franceschini G (2015) Acquired lecithin:cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease. J Intern Med 277:552\u2013561","journal-title":"J Intern Med"},{"key":"4289_CR30","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.bbrc.2014.03.053","volume":"446","author":"C Li","year":"2014","unstructured":"Li C, Li H, Zhang T, Li J, Liu L, Chang J (2014) Discovery of Apo-A1 as a potential bladder cancer biomarker by urine proteomics and analysis. Biochem Biophys Res Commun 446:1047\u20131052","journal-title":"Biochem Biophys Res Commun"},{"key":"4289_CR31","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1600-6143.2012.04338.x","volume":"13","author":"J Lopez-Hellin","year":"2013","unstructured":"Lopez-Hellin J, Cantarell C, Jimeno L, Sanchez-Fructuoso A, Puig-Gay N, Guirado L, Vilarino N, Gonzalez-Roncero FM, Mazuecos A, Lauzurica R, Burgos D, Plumed JS, Jacobs-Cacha C, Jimenez C, Fernandez A, Fernandez-Alvarez P, Torregrosa V, Nieto JL, Meseguer A, Alonso A (2013) A form of apolipoprotein a-I is found specifically in relapses of focal segmental glomerulosclerosis following transplantation. Am J Transplant 13:493\u2013500","journal-title":"Am J Transplant"},{"key":"4289_CR32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1681\/ASN.2013090950","volume":"25","author":"LE Dickson","year":"2014","unstructured":"Dickson LE, Wagner MC, Sandoval RM, Molitoris BA (2014) The proximal tubule and albuminuria: really! J Am Soc Nephrol 25:443\u2013453","journal-title":"J Am Soc Nephrol"},{"key":"4289_CR33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/jcla.21591","volume":"27","author":"K Yoshifumi","year":"2013","unstructured":"Yoshifumi K, Tomoaki T, Shinichi M, Tohru A, Tatsumi M, Zensuke O (2013) Semiquantitative analysis of apolipoprotein A-I modified by advanced glycation end products in diabetes mellitus. J Clin Lab Anal 27:231\u2013236","journal-title":"J Clin Lab Anal"},{"key":"4289_CR34","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1161\/ATVBAHA.113.303044","volume":"34","author":"B Hewing","year":"2014","unstructured":"Hewing B, Parathath S, Barrett T, Chung WK, Astudillo YM, Hamada T, Ramkhelawon B, Tallant TC, Yusufishaq MS, Didonato JA, Huang Y, Buffa J, Berisha SZ, Smith JD, Hazen SL, Fisher EA (2014) Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 34:779\u2013789","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4289_CR35","doi-asserted-by":"publisher","first-page":"9176","DOI":"10.1074\/jbc.RA117.001099","volume":"293","author":"LS May-Zhang","year":"2018","unstructured":"May-Zhang LS, Yermalitsky V, Huang J, Pleasent T, Borja MS, Oda MN, Jerome WG, Yancey PG, Linton MF, Davies SS (2018) Modification by isolevuglandins, highly reactive gamma-ketoaldehydes, deleteriously alters high-density lipoprotein structure and function. J Biol Chem 293:9176\u20139187","journal-title":"J Biol Chem"},{"key":"4289_CR36","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1681\/ASN.2003100861","volume":"16","author":"E Erkan","year":"2005","unstructured":"Erkan E, Garcia CD, Patterson LT, Mishra J, Mitsnefes MM, Kaskel FJ, Devarajan P (2005) Induction of renal tubular cell apoptosis in focal segmental glomerulosclerosis: roles of proteinuria and Fas-dependent pathways. J Am Soc Nephrol 16:398\u2013407","journal-title":"J Am Soc Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-019-04289-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-019-04289-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-019-04289-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T03:51:57Z","timestamp":1721447517000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-019-04289-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,23]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["4289"],"URL":"https:\/\/doi.org\/10.1007\/s00467-019-04289-5","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,23]]},"assertion":[{"value":"10 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board at Vanderbilt University Medical Center. A waiver of consent was granted for patients who submitted urine as part of their routine care. Controls were consented and asked to provide a urine sample for study purposes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}